Citadel Advisors
NWBO

Citadel Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Citadel Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-19,300
Closed -$11K – 8430
2016
Q3 		$11K Sell
19,300
-800
-4% -$366 ﹤0.01% 7141
2016
Q2 		$12K Sell
20,100
-1,100
-5% -$1.17K ﹤0.01% 6718
2016
Q1 		$31K Sell
21,200
-14,600
-41% -$28.8K ﹤0.01% 6375
2015
Q4 		$115K Sell
35,800
-24,100
-40% -$116K ﹤0.01% 6538
2015
Q3 		$374K Buy
59,900
+3,100
+5% +$29K ﹤0.01% 5239
2015
Q2 		$564K Sell
56,800
-18,300
-24% -$160K ﹤0.01% 4781
2015
Q1 		$553K Buy
75,100
+10,500
+16% +$70.7K ﹤0.01% 4748
2014
Q4 		$346K Sell
64,600
-500
-0.8% -$2.56K ﹤0.01% 5229
2014
Q3 		$327K Buy
65,100
+41,400
+175% +$254K ﹤0.01% 5158
2014
Q2 		$159K Buy
23,700
+15,900
+204% +$101K ﹤0.01% 5820
2014
Q1 		$56K Buy
+7,800
New +$46.2K ﹤0.01% 6694

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Citadel Advisors's NWBO Position: Q4 2016 in Review

Citadel Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 17,627 shares — an estimated $10K sold.

Citadel Advisors first reported a position in NWBO in Q1 2014 and held it in 8 quarters. The position peaked at $192K in Q2 2014. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Citadel Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Citadel Advisors sold 17,627 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $10K.
  • Citadel Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 8 quarters.
  • Citadel Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $192K in Q2 2014.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.